Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06159556
Other study ID # 5230190
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 2024
Est. completion date December 20, 2024

Study information

Verified date June 2024
Source Loma Linda University
Contact Amandeep Wright, MPH
Phone 909-558-4300
Email amawright@llu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the proposed study is two-fold: to determine whether the intake of peanuts (a) enhances immune function and (b) produces a desirable impact on selected cardiometabolic biomarkers and risk factors.


Description:

The aim of the proposed study is two-fold: to determine whether the intake of peanuts (a) enhances immune function and (b) produces a desirable impact on selected cardiometabolic biomarkers and risk factors . To accomplish this objective, a human dietary intervention trial (RCT) with peanuts is proposed. The proposed study is a 12-week parallel-group, free-living, observer-blind, randomized controlled dietary intervention trial. This study will examine the effects of peanuts on markers of immune function, cardiometabolic markers and risk factors and upper respiratory tract infections, in 80 adult male and female volunteers.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 20, 2024
Est. primary completion date December 20, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - adults between the ages of 18-70 years Exclusion Criteria: - known intolerance or allergy to peanuts - bad dentures unable to chew peanuts - regular intake of peanuts and/or other nuts (>3 ounces/week) - use of immune-boosting supplements - exposure to antibiotics and corticoids immediately prior to the study - use of other medications or supplements that can interfere with the immune functions - Individuals that received any vaccination (i.e flu or Covid 19) 6 months prior to the start of the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Peanut intake
Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks

Locations

Country Name City State
United States Loma Linda University School of Public Health Loma Linda California

Sponsors (2)

Lead Sponsor Collaborator
Loma Linda University California Walnut Commission

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in lymphocyte populations Immunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naive and memory cells and B cells baseline to 12 weeks
Primary Changes in Lymphocyte activity The production of lymphocytes will be measured in the supernatant using enzyme linked immunosorbent assay (ELISA) baseline to 12 weeks
Primary Changes in cytokine production The cytokines produced due to lymphocyte activity will be measured in the supernatant using enzyme linked immunosorbent assay (ELISA) baseline to 12 weeks
Primary Changes in serum inflammatory cytokine concentration changes in the concentrations of the inflammatory cytokines will be performed on serum using enzyme linked immunoassay (ELISA) will include hs-CRP, interleukin (IL)-1B, IL-6, TNF a, IL-10 and IFN-?, MCP1, Eotaxin, E-selectin, RANTES and Pentraxin-3 baseline to 12 weeks
Primary Changes in the serum lipid concentration This is a composite measurement which will measure the changes in the levels of serum low density cholesterol, high density cholesterol, non- high density cholesterol and triglycerides baseline to 12 weeks
Primary Changes in insulin resistance Change in insulin resistance will be measured using the Hemostatic Model Assessment calculator version 2 (HOMA2-IR) baseline to 12 weeks
Primary Changes in Hemoglobin A1c Change in Hemoglobin A1c will be measured by cation-exchange high-performance liquid chromatography method baseline to 12 weeks
Primary Changes in body weight A change in body weight for both the peanut and control group will be measured using an In Body machine at the baseline and end of intervention baseline to 12 weeks
Primary changes in systolic and diastolic blood pressure Seated systolic and diastolic blood pressure will be measured at baseline and end of intervention utilizing Omron -Model HEM-7471 C device. Three measurements will be taken after a five-minute rest period, 1 minute apart, and the last two recordings will be averaged for analysis. baseline to 12 weeks
Primary changes in percentage body fat A change in the percentage of body fat for both the peanut and control group will be measured using an In Body machine at the baseline and end of intervention baseline to 12 weeks
Secondary changes in upper respiratory infection questionnaire score Upper respiratory tract infections will be tracked using the Jackson and Dowling questionnaire. The questionnaire will be completed daily by participants, either manually or electronically , throughout the 12-week study period. The scale for the questionnaire is from 0-42. The higher score means worse outcome. baseline to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05515263 - Snack Foods and Their Impact on the Immune Response Following Influenza Vaccination N/A
Completed NCT02872311 - Open-Label Influenza Vaccine Evaluation N/A
Completed NCT01861613 - Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students Phase 4
Completed NCT03982069 - Immunologic Response to FluMist vs. Flucelvax Phase 4
Recruiting NCT06041867 - Agaricus Bisporus and Influenza Vaccination Response N/A
Completed NCT03614975 - Immunologic Response to Influenza Vaccination in Children and Adolescents Phase 4
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03875703 - Post-Vaccination Biological Collection
Completed NCT00902278 - Immune Responses Induced by Different Licensed Influenza Vaccines N/A
Completed NCT00346619 - Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults Phase 1
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Active, not recruiting NCT05534893 - Effect of Blueberries on Immunity and Response to Flu Vaccination N/A
Completed NCT05970887 - Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines Phase 4
Completed NCT05706350 - Plant Stanol Esters and Influenza Vaccination N/A
Completed NCT03167593 - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Phase 2
Completed NCT04386408 - Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections Phase 1
Completed NCT02933931 - Immune Durability After VSV-EBOV Vaccination
Recruiting NCT01289535 - Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years Phase 4
Active, not recruiting NCT02441426 - Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A